Literature DB >> 24477913

Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung.

Isabel Vega-Carrascal1, David A Bergin, Oliver J McElvaney, Cormac McCarthy, Nessa Banville, Kerstin Pohl, Mitsuomi Hirashima, Vijay K Kuchroo, Emer P Reeves, Noel G McElvaney.   

Abstract

The T cell Ig and mucin domain-containing molecule (TIM) family of receptors have emerged as potential therapeutic targets to correct abnormal immune function in chronic inflammatory conditions. TIM-3 serves as a functional receptor in structural cells of the airways and via the ligand galectin-9 (Gal-9) can modulate the inflammatory response. The aim of this study was to investigate TIM-3 expression and function in neutrophils, focusing on its potential role in cystic fibrosis (CF) lung disease. Results revealed that TIM-3 mRNA and protein expression values of circulating neutrophils were equal between healthy controls (n = 20) and people with CF (n = 26). TIM-3 was detected on resting neutrophil membranes by FACS analysis, and expression levels significantly increased post IL-8 or TNF-α exposure (p < 0.05). Our data suggest a novel role for TIM-3/Gal-9 signaling involving modulation of cytosolic calcium levels. Via TIM-3 interaction, Gal-9 induced neutrophil degranulation and primed the cell for enhanced NADPH oxidase activity. Killing of Pseudomonas aeruginosa was significantly increased upon bacterial opsonization with Gal-9 (p < 0.05), an effect abrogated by blockade of TIM-3 receptors. This mechanism appeared to be Gram-negative bacteria specific and mediated via Gal-9/ LPS binding. Additionally, we have demonstrated that neutrophil TIM-3/Gal-9 signaling is perturbed in the CF airways due to proteolytic degradation of the receptor. In conclusion, results suggest a novel neutrophil defect potentially contributing to the defective bacterial clearance observed in the CF airways and suggest that manipulation of the TIM-3 signaling pathway may be of therapeutic value in CF, preferably in conjunction with antiprotease treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24477913      PMCID: PMC4997615          DOI: 10.4049/jimmunol.1300711

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  81 in total

1.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  beta-1,2-linked oligomannosides from Candida albicans bind to a 32-kilodalton macrophage membrane protein homologous to the mammalian lectin galectin-3.

Authors:  C Fradin; D Poulain; T Jouault
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

Review 4.  Emerging Tim-3 functions in antimicrobial and tumor immunity.

Authors:  Kaori Sakuishi; Pushpa Jayaraman; Samuel M Behar; Ana C Anderson; Vijay K Kuchroo
Journal:  Trends Immunol       Date:  2011-06-21       Impact factor: 16.687

Review 5.  Clonal epidemiology of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Nina Cramer; Lutz Wiehlmann; Burkhard Tümmler
Journal:  Int J Med Microbiol       Date:  2010-10-14       Impact factor: 3.473

6.  Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway.

Authors:  Yumiko Kashio; Kazuhiro Nakamura; Mohammad J Abedin; Masako Seki; Nozomu Nishi; Naoko Yoshida; Takanori Nakamura; Mitsuomi Hirashima
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

Review 7.  The costimulatory role of TIM molecules.

Authors:  Roselynn Rodriguez-Manzanet; Rosemarie DeKruyff; Vijay K Kuchroo; Dale T Umetsu
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

8.  Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways.

Authors:  Rabindra Tirouvanziam; Yael Gernez; Carol K Conrad; Richard B Moss; Iris Schrijver; Colleen E Dunn; Zoe A Davies; Leonore A Herzenberg; Leonard A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-11       Impact factor: 11.205

9.  Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation.

Authors:  Masafumi Nakayama; Hisaya Akiba; Kazuyoshi Takeda; Yuko Kojima; Masaaki Hashiguchi; Miyuki Azuma; Hideo Yagita; Ko Okumura
Journal:  Blood       Date:  2009-02-17       Impact factor: 22.113

10.  Identification of the cystic fibrosis gene: chromosome walking and jumping.

Authors:  J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

View more
  18 in total

Review 1.  Galectin-9: From cell biology to complex disease dynamics.

Authors:  Sebastian John; Rashmi Mishra
Journal:  J Biosci       Date:  2016-09       Impact factor: 1.826

2.  Negative regulation of Nod-like receptor protein 3 inflammasome activation by T cell Ig mucin-3 protects against peritonitis.

Authors:  Wei Wang; Qingzhu Shi; Shuaijie Dou; Ge Li; Xinhui Shi; Xingwei Jiang; Zhiding Wang; Dandan Yu; Guojiang Chen; Renxi Wang; He Xiao; Chunmei Hou; Jiannan Feng; Beifen Shen; Yuanfang Ma; Gencheng Han
Journal:  Immunology       Date:  2017-09-18       Impact factor: 7.397

3.  Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis.

Authors:  Xingwei Jiang; Tingting Zhou; Yan Xiao; Jiahui Yu; Shuaijie Dou; Guojiang Chen; Renxi Wang; He Xiao; Chunmei Hou; Wei Wang; Qingzhu Shi; Jiannan Feng; Yuanfang Ma; Beifen Shen; Yan Li; Gencheng Han
Journal:  Oncoimmunology       Date:  2016-08-03       Impact factor: 8.110

Review 4.  Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and function.

Authors:  Emer P Reeves; Cormac McCarthy; Oliver J McElvaney; Maya Sakthi N Vijayan; Michelle M White; Danielle M Dunlea; Kerstin Pohl; Noreen Lacey; Noel G McElvaney
Journal:  World J Crit Care Med       Date:  2015-08-04

5.  Detection of Reactive Oxygen Species in Human Neutrophils Under Various Conditions of Exposure to Galectin.

Authors:  Lilian Cataldi Rodrigues; Daniel Giuliano Cerri; Cleni M Marzocchi-Machado; Richard D Cummings; Sean R Stowell; Marcelo Dias-Baruffi
Journal:  Methods Mol Biol       Date:  2022

6.  Alarmin function of galectin-9 in murine respiratory tularemia.

Authors:  Anthony L Steichen; Tanner J Simonson; Sharon L Salmon; Dennis W Metzger; Bibhuti B Mishra; Jyotika Sharma
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

7.  Blockage of Galectin-receptor Interactions by α-lactose Exacerbates Plasmodium berghei-induced Pulmonary Immunopathology.

Authors:  Jinfeng Liu; Shiguang Huang; Xin-Zhuan Su; Jianping Song; Fangli Lu
Journal:  Sci Rep       Date:  2016-08-24       Impact factor: 4.379

8.  Protective effect of Galectin-9 in murine model of lung emphysema: Involvement of neutrophil migration and MMP-9 production.

Authors:  Yuko Horio; Hidenori Ichiyasu; Keisuke Kojima; Naoki Saita; Yohei Migiyama; Toyohisa Iriki; Kazuhiko Fujii; Toshiro Niki; Mitsuomi Hirashima; Hirotsugu Kohrogi
Journal:  PLoS One       Date:  2017-07-12       Impact factor: 3.240

9.  Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients.

Authors:  Kristian Taipale; Siri Tähtinen; Riikka Havunen; Anniina Koski; Ilkka Liikanen; Päivi Pakarinen; Riitta Koivisto-Korander; Matti Kankainen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Oncotarget       Date:  2018-01-05

Review 10.  The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals.

Authors:  Danielle M Dunlea; Laura T Fee; Thomas McEnery; Noel G McElvaney; Emer P Reeves
Journal:  J Inflamm Res       Date:  2018-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.